Expanding therapeutic implications, DORAs (e.g., daridorexant, lemborexant) show potential beyond insomnia for metabolic disorders, improving glucose tolerance in obesity models by blocking OX2R-driven overeating and SNS hyperactivity. The gene discussed is HCRTR2; the disease is obesity due to melanocortin 4 receptor deficiency.